GTCM
TARA icon

Gyon Technologies Capital Management’s Protara Therapeutics TARA Stock Holding History

Gyon Technologies Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,553
Closed -$85K – 548
2021
Q4 		$85K Buy
+12,553
New +$86.5K 0.02% 541

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gyon Technologies Capital Management's TARA Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Protara Therapeutics (TARA) in Q1 2022, closing a stake of 12,553 shares — an estimated $85K sold.

Gyon Technologies Capital Management first reported a position in TARA in Q4 2021 and held it in 1 quarter. The position peaked at $85K in Q4 2021. 35 funds tracked by Wall St. Rank hold TARA as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Protara Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 12,553 Protara Therapeutics shares in Q1 2022, an estimated $85K.
  • Gyon Technologies Capital Management first reported a position in Protara Therapeutics in Q4 2021 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Protara Therapeutics position peaked at $85K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.